Publications by authors named "Thomas Burris"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

51,333

Total Likes

1,549

Extended Reach

1,641,804

Social Features

79
L
Limited effects of the REV-ERB agonist SR9009 after mouse spinal cord contusion: Reduced acute pathology with unaffected functional recovery and chronic white matter loss.
Lukasz P Slomnicki, Emily Hodges, Christine Armstrong, Johnny Morehouse, Darlene Burke, Thomas P Burris

Neurosci Lett· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.
Cyrielle Billon, Kevin Appourchaux, Isabelle Côté, Thomas P Burris

J Pharmacol Exp Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury.
Lingaiah Maram, Aurore-Cecile Valfort, Mohammad Homaidur Rahman, Hazem E Okda, Mohamed Elagawany, Thomas P Burris

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REV-ERBα regulates brain NAD levels and tauopathy via an NFIL3-CD38 axis.
Jiyeon Lee, Ryeonghwa Kang, Sohui Park, Ibrahim O Saliu, Minsoo Son, Thomas P Burris

Nat Aging· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cold exposure induces the constitutively active thermogenic receptor, GPR3, via ERRα and ERRγ.
Olivia Sveidahl Johansen, Rebecca L McIntyre, Janane F Rahbani, Qiaoqiao Zhang, Charlotte Scholtes, Thomas P Burris

Mol Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iodine-promoted oxidative cross-coupling for the synthesis of ()-2-(3-oxo-3-phenylprop-1-en-1-yl)-3-phenylquinazolin-4(3)-one C-H activation: development of synthetic TLX agonists.
Lingaiah Maram, Puhan Zhao, Thomas Koelblen, Lamees Hegazy, Thomas P Burris

Org Biomol Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of radioligand binding assays for REV-ERBα and REV-ERBβ.
Thomas Koelblen, Elise P Burris, Thomas P Burris

Anal Biochem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Animal models for development of anti-obesity drugs in the age of GLP-1 agents.
Alexander Culver, Keith Stayrook, Michele Comerota, Adrian Oblak, Thomas Burris

Expert Opin Drug Discov· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins.
Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Thomas P Burris

Mol Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB.
McKenna Losby, Matthew Hayes, Aurore Valfort, Danesh H Sopariwala, Ryan Sanders, Thomas P Burris

Mol Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release.
Joshua M Nicholson, Dexi Yang, Thomas Koelblen, Eric L Hu, Christopher C Coss, Thomas P Burris

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Make Glucocorticoids Safer.
Thomas P Burris

J Pharmacol Exp Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Functional Fatty Acids to Potent and Selective Natural-Product-Inspired Mimetics via Conformational Profiling.
Lauren E Markham, Thomas Koelblen, Harry R Chobanian, Ariele Viacava Follis, Thomas P Burris

ACS Cent Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.
Xiaoxin X Wang, Komuraiah Myakala, Andrew E Libby, Ewa Krawczyk, Julia Panov, Thomas P Burris

Am J Pathol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Thomas P Burris, Ian Mitchelle S de Vera, Isabelle Cote, Colin A Flaveny, Udayanga S Wanninayake

Pharmacol Rev· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.
Carissa S Hampton, Sadichha Sitaula, Cyrielle Billon, Keith Haynes, Amer Avdagic, Sheryl L Burris, Thomas P Burris

Eur J Med Chem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rev-erbα agonists suppresses TGFβ1-induced fibroblast-to-myofibroblast transition and pro-fibrotic phenotype in human lung fibroblasts.
Chandrashekhar Prasad, Kameron Hahn, Santosh Kumar Duraisamy, Matthias A Salathe, Steven K Huang, Thomas P Burris

Biochem Biophys Res Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REV-ERB activation as a novel pharmacological approach for treating inflammatory pain.
Sangeet Makhija, Joshua D Griffett, Giri Babu Veerakanellore, Thomas P Burris, Bahaa Elgendy

Front Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assigning pathogenicity for TAB2 variants using a novel scalable functional assay and expanding TAB2 disease spectrum.
Weiyi Xu, Andrea Graves, Monika Weisz-Hubshman, Lamees Hegazy, Christina Magyar, Thomas Burris

Hum Mol Genet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
Kristine Griffett, Thomas P Burris

Front Med (Lausanne)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB.
Meghan H Murray, Aurore Cecile Valfort, Thomas Koelblen, Céline Ronin, Fabrice Ciesielski, Thomas P Burris

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REV-ERB is essential in cardiac fibroblasts homeostasis.
Xiaokang Luo, Shiyang Song, Lei Qi, Chih-Liang Tien, Hui Li, Thomas Burris

Front Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis